Cash flow generation remains highly erratic, highlighted by an OCF/NI ratio that reached a volatile peak of 9.30 in 2025Q2 before shifting to a negative 1.14 in 2026Q1.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Cash from Operations | 4.06M | 1.84M | 9.42M | 14.68M | 8.21M | 13.84M | 11.18M | 7.52M | 5.45M | 156.44K | -10.85M | -6.8M | -437.44K | 422.22K | 2.18M |
| Operating CF Margin % | - | 3.35% | 18.05% | 31.24% | 8.11% | 17.3% | 19.06% | 15.52% | 17.15% | 0.62% | -52.85% | -49.12% | -6.15% | 7.09% | 78.13% |
| Operating CF Growth % | 170.92% | -80.47% | -35.85% | 78.79% | -40.7% | 23.79% | 48.67% | 37.96% | 3385.12% | 101.44% | -59.6% | -1453.68% | -203.61% | -80.6% | - |
| Net Income | 3.24M | 2.91M | -8.53M | -9.75M | 626.71K | 7.57M | 13.17M | 3.32M | 253.08K | -3.28M | -15.17M | -8.8M | -3.03M | 155.63K | -736.29K |
| Depreciation & Amortization | 1.71M | 1.71M | 4.72M | 8.58M | 6.65M | 3.92M | 2.73M | 1.9M | 1.56M | 2.02M | 2.57M | 1.27M | 210.12K | 70.72K | 49.81K |
| Stock-Based Compensation | 657.28K | 1.3M | 1.68M | 1.74M | 1.27M | 1.06M | 885.98K | 720.65K | 628.43K | 594.37K | 1.12M | 825.14K | 101.83K | 0 | 0 |
| Deferred Taxes | 93.07K | 93.07K | -55.56K | 10.9M | 0 | -1.78M | 0 | 1.78K | -77.02K | 15.73K | 120.7K | 40.8K | 1.76M | -552.3K | -576.1K |
| Other Non-Cash Items | 6.11M | 5.39M | 10.5M | 2.41M | 3.61M | -7.77K | -6.04M | -18.89K | 308.98K | 423.72K | 3.13M | -1.33M | 112.91K | -5.55K | 2.86M |
| Working Capital Changes | -6.82M | -9.56M | 1.1M | 798.62K | -3.95M | 3.09M | 433.24K | 1.6M | 2.78M | 380.52K | -2.61M | 1.2M | 410.81K | 753.71K | 3.44M |
| Change in Receivables | 532.37K | 1.53M | -1.65M | 192.35K | -154.67K | -1.64M | 794.59K | -1.84M | -75.33K | -124.11K | -999.52K | -99.96K | -369.53K | -287.76K | -79.69K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.39M | 1.11M | -718.64K | -998.42K | 1.25M | -570.71K | 881.11K | -276.08K |
| Change in Payables | -588.3K | -391.13K | 68.26K | -1.38M | 0 | -14.37K | 0 | 75.89K | 63.57K | -36.75K | -953.08K | -291.48K | 1.04M | 125.39K | -136.36K |
| Cash from Investing | 6.33M | 6.27M | -631.55K | -6.19M | -17.9M | -12.75M | -4.6M | -7.14M | -1.24M | -372.85K | -2.7M | -10.01M | -2.06M | -231.06K | -174.04K |
| Capital Expenditures | -1.41M | -1.5M | -1.19M | -5M | -5.9M | -6.99M | -3.16M | -4.17M | -1.39M | -449.2K | -1.89M | -5.14M | -1.17M | -241.41K | -131.31K |
| CapEx % of Revenue | 2.48% | 2.74% | 2.27% | 10.64% | 5.83% | 8.74% | 5.38% | 8.6% | 4.37% | 1.79% | 9.22% | 37.16% | 16.4% | 4.05% | 4.71% |
| Acquisitions | 7.78M | 7.78M | 554.1K | -1.19M | -12.11M | -5.77M | -534K | -3.12M | -100K | 0 | -839K | -4.93M | -900K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -40.1K | 0 | 0 | 0 | 105.2K | 0 | -910.78K | 149.35K | 245.71K | 76.35K | 35.91K | 53.89K | 511.68K | 10.35K | -42.73K |
| Cash from Financing | -11.87M | -9.81M | -2M | 174.12K | 328.61K | -2M | 5.6M | -596.96K | 326.3K | 1.42M | -239.85K | 12.81M | 19.78M | -240K | 0 |
| Debt Issued (Net) | 0 | -4.35K | -2.03M | -24.43K | -49.85K | -2.81M | 1.89M | -1.12M | 0 | 768.5K | -436.35K | -218.5K | 0 | 0 | 0 |
| Equity Issued (Net) | -11.87M | -9.8M | 24.13K | 198.55K | -5.8K | 0 | -32.07K | -20.18K | 0 | 292.67K | 208.96K | 14.37M | 22.43M | -240K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -12.52M | -11.32M | -9.58K | -3.83K | -5.8K | 0 | -32.07K | -20.18K | -4.81K | -2.65K | -83.39K | 0 | 0 | -240K | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 384.27K | 811.59K | 3.74M | 545.18K | 326.3K | 361.6K | -12.46K | -1.35M | -2.65M | 0 | 0 |
| Net Change in Cash | -1.47M | -1.69M | 6.78M | 8.66M | -9.36M | -907.29K | 12.18M | -213.07K | 4.53M | 1.21M | -13.78M | -4M | 17.28M | -48.84K | 2M |
| Free Cash Flow | 2.66M | 334.72K | 8.23M | 9.68M | 2.31M | 6.85M | 8.03M | 3.36M | 4.06M | -292.76K | -12.74M | -11.94M | -1.6M | 180.81K | 2.04M |
| FCF Margin % | 4.69% | 0.61% | 15.78% | 20.6% | 2.28% | 8.57% | 13.68% | 6.93% | 12.78% | -1.16% | -62.07% | -86.29% | -22.54% | 3.03% | 73.42% |
| FCF Growth % | 49.06% | -95.93% | -14.97% | 318.89% | -66.29% | -14.61% | 139.12% | -17.38% | 1487.79% | 97.7% | -6.72% | -644.14% | -987.28% | -91.16% | - |
| FCF per Share | 0.19 | 0.02 | 0.54 | 0.66 | 0.16 | 0.46 | 0.55 | 0.23 | 0.29 | -0.02 | -1.00 | -1.19 | -0.29 | 0.02 | 0.22 |
| FCF Conversion (FCF/Net Income) | 0.82x | 0.63x | -1.62x | -1.51x | 13.10x | 1.83x | 0.85x | 2.26x | 21.54x | -0.05x | 0.71x | 0.77x | 0.14x | 2.71x | -2.96x |
| Interest Paid | 12.64K | 0 | 69.44K | 173.06K | 71.25K | 0 | 42.83K | 0 | 0 | 108.02K | 15.26K | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 610.49K | 569.76K | 0 | 0 | 0 | 0 | 0 | 29.32K | 11.25K | 0 | 420.25K | 0 | 0 |
Operating cash flow volatility
As reported in financial statements, JYNT exhibits extreme volatility in cash conversion, with the OCF/NI ratio swinging from a high of 9.30 in 2025Q2 to a negative 3.82 in 2025Q1, indicating that reported net income is a poor proxy for the company's actual cash-generating capacity.
The wide variance between net income and operating cash flow suggests that non-cash items and significant working capital swings are heavily influencing the bottom line. Investors should monitor whether this disconnect stems from the timing of franchise fee recognition or aggressive corporate clinic expansion costs that do not align with GAAP earnings.
Based on recent quarterly filings, JYNT's free cash flow trajectory remains highly erratic, oscillating between a peak of $3.8 million in 2024Q4 and a deficit of $4.0 million in 2025Q1, reflecting a business model that struggles to maintain consistent cash flow margins across different operating periods.
The inability to sustain positive free cash flow suggests that the company's capital-intensive strategy of acquiring and operating corporate clinics may be outpacing its ability to generate organic cash. This inconsistency warrants further investigation into whether the current cost structure can support long-term profitability without recurring external capital support.
According to the provided cash flow data, working capital changes have been a major source of instability, with a $3.6 million outflow in 2026Q1 following a $1.3 million inflow in 2024Q4, highlighting the company's sensitivity to timing differences in collections and franchise-related payables.
These sharp fluctuations in working capital suggest that the company's cash position is highly susceptible to the operational cadence of its franchise network. Such volatility may indicate challenges in managing the cash cycle effectively as the company scales its corporate-owned footprint.
As evidenced by recent financial disclosures, JYNT has utilized significant cash for share repurchases, including $9.0 million in 2025Q4, even while operating cash flow remains inconsistent, suggesting a management focus on capital return that may conflict with the need for internal reinvestment in clinic operations.
The decision to prioritize buybacks during periods of negative or volatile cash flow appears to be a high-risk capital allocation strategy. Investors should monitor whether these outflows limit the company's flexibility to address potential labor cost inflation or future operational requirements within its corporate clinic segment.
Quick answers to the most common questions about buying JYNT stock.
The Joint Corp. (JYNT) generated $1.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
The Joint Corp. (JYNT) generated $0.3M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
The Joint Corp. (JYNT) spent $1.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, The Joint Corp. (JYNT) spent $11.3M on share repurchases. This shows the company's commitment to returning capital to its equity investors.